🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 2 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 25/02/1997 | 25,75 | 25,75 | 23,00 | 23,63 | -7,58% | 10,68% | 811.000 |
| 24/02/1997 | 25,00 | 26,13 | 24,31 | 25,56 | +2,76% | 7,25% | 529.600 |
| 21/02/1997 | 24,88 | 26,38 | 24,88 | 24,88 | -1,00% | 6,03% | 544.000 |
| 20/02/1997 | 24,75 | 25,13 | 24,38 | 25,13 | +2,03% | 3,03% | 292.800 |
| 19/02/1997 | 24,50 | 25,25 | 24,13 | 24,63 | +1,03% | 4,59% | 609.400 |
| 18/02/1997 | 23,88 | 24,75 | 23,44 | 24,38 | +2,23% | 5,50% | 392.600 |
| 14/02/1997 | 24,13 | 24,50 | 23,63 | 23,84 | -0,13% | 3,63% | 375.600 |
| 13/02/1997 | 23,50 | 24,50 | 23,00 | 23,88 | +3,80% | 6,38% | 463.200 |
| 12/02/1997 | 23,00 | 23,00 | 21,50 | 23,00 | +1,66% | 6,52% | 393.000 |
| 11/02/1997 | 22,88 | 23,63 | 22,44 | 22,63 | -1,63% | 5,19% | 293.800 |
| 10/02/1997 | 22,75 | 23,06 | 22,50 | 23,00 | +1,66% | 2,47% | 235.200 |
| 07/02/1997 | 23,13 | 23,38 | 22,38 | 22,63 | -1,63% | 4,32% | 454.400 |
| 06/02/1997 | 23,00 | 23,38 | 22,75 | 23,00 | +0,00% | 2,72% | 165.600 |
| 05/02/1997 | 23,63 | 23,75 | 22,75 | 23,00 | -1,60% | 4,23% | 264.800 |
| 04/02/1997 | 24,25 | 24,56 | 23,38 | 23,38 | -3,36% | 4,90% | 224.200 |
| 03/02/1997 | 24,75 | 25,13 | 23,88 | 24,19 | -1,28% | 5,05% | 320.200 |
| 31/01/1997 | 24,13 | 25,63 | 24,00 | 24,50 | +1,55% | 6,74% | 722.400 |
| 30/01/1997 | 22,88 | 24,31 | 22,63 | 24,13 | +6,34% | 7,38% | 425.000 |
| 29/01/1997 | 23,31 | 23,63 | 22,50 | 22,69 | -2,16% | 4,83% | 388.600 |
| 28/01/1997 | 23,00 | 23,94 | 22,63 | 23,19 | +3,34% | 5,71% | 958.600 |
| 27/01/1997 | 22,25 | 22,50 | 21,13 | 22,44 | +7,49% | 6,18% | 472.800 |
| 24/01/1997 | 20,81 | 21,00 | 20,44 | 20,88 | +2,14% | 2,70% | 735.800 |
| 23/01/1997 | 20,88 | 21,38 | 20,38 | 20,44 | -1,51% | 4,79% | 1.259.600 |
| 22/01/1997 | 21,13 | 21,88 | 20,00 | 20,75 | +0,00% | 8,88% | 1.062.800 |
| 21/01/1997 | 22,25 | 22,75 | 20,63 | 20,75 | -5,68% | 9,55% | 933.600 |
| 20/01/1997 | 24,13 | 24,13 | 21,88 | 22,00 | -8,81% | 9,33% | 1.138.400 |
| 17/01/1997 | 24,38 | 25,75 | 24,00 | 24,13 | -1,78% | 7,18% | 949.600 |
| 16/01/1997 | 23,75 | 24,69 | 23,38 | 24,56 | +6,22% | 5,53% | 1.129.400 |
| 15/01/1997 | 22,50 | 23,13 | 21,88 | 23,13 | +2,21% | 5,56% | 555.200 |
| 14/01/1997 | 23,75 | 23,88 | 22,56 | 22,63 | -4,74% | 5,53% | 1.397.800 |